MeSH term | MeSH ID | Detail |
---|---|---|
Sacroiliitis | D058566 | 1 associated lipids |
Chlamydial Pneumonia | D061387 | 2 associated lipids |
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with clarithromycin
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Saadat A et al. | The formulation, chemical and physical characterisation of clarithromycin-based macrolide solution pressurised metered dose inhaler. | 2014 | J. Pharm. Pharmacol. | pmid:24329164 |
Rajput P et al. | Bifunctional capsular dosage form: novel fanicular cylindrical gastroretentive system of clarithromycin and immediate release granules of ranitidine HCl for simultaneous delivery. | 2014 | Int J Pharm | pmid:24309435 |
Katayama M et al. | Preliminary study of effects of multiple oral dosing of clarithromycin on the pharmacokinetics of cyclosporine in dogs. | 2014 | J. Vet. Med. Sci. | pmid:24189617 |
Papastergiou V et al. | Current and future insights in H. pylori eradication regimens: the need of tailoring therapy. | 2014 | Curr. Pharm. Des. | pmid:24180408 |
Tan X and Song Z | Human saliva-based quantitative monitoring of clarithromycin by flow injection chemiluminescence analysis: a pharmacokinetic study. | 2014 | Appl. Biochem. Biotechnol. | pmid:24166104 |
Shahbazi Niaz M et al. | Investigation into physical-chemical variables affecting the manufacture and dissolution of wet-milled clarithromycin nanoparticles. | 2014 | Pharm Dev Technol | pmid:24093825 |
Zhao Y and Hu ZY | Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate. | 2014 | Br. J. Pharmacol. | pmid:24283665 |
Harvey E and Varatharaj A | Round pneumonia. | 2014 | QJM | pmid:23708793 |
Tsovolou EC et al. | Effect of clarithromycin in experimental empyema by multidrug-resistant Pseudomonas aeruginosa. | 2014 | APMIS | pmid:23656439 |
Yamada K et al. | Azithromycin inhibits MUC5AC induction via multidrug-resistant Acinetobacter baumannii in human airway epithelial cells. | 2014 | Pulm Pharmacol Ther | pmid:24910464 |
Tranos P et al. | Bilateral diffuse iris atrophy after the use of oral clarithromycin. | 2014 | Cutan Ocul Toxicol | pmid:23763291 |
Page SR and Yee KC | Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin. | 2014 | Intern Med J | pmid:25041770 |
Phillips RO et al. | Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease. | 2014 | Antimicrob. Agents Chemother. | pmid:24323473 |
El-Garem Y et al. | Seminal Helicobacter pylori treatment improves sperm motility in infertile asthenozoospermic men. | 2014 | Urology | pmid:25432826 |
Yoon KH et al. | Clarithromycin-based standard triple therapy can still be effective for Helicobacter pylori eradication in some parts of the Korea. | 2014 | J. Korean Med. Sci. | pmid:25246742 |
Matongo F and Nwodo UU | In vitro assessment of Helicobacter pylori ureases inhibition by honey fractions. | 2014 | Arch. Med. Res. | pmid:25240315 |
Martos M et al. | Clarithromycin for first-line treatment of Helicobacter pylori infection after culture in high-resistance regions. | 2014 | Eur J Gastroenterol Hepatol | pmid:25229983 |
Cicek-Senturk G et al. | Acute mercury poisoning presenting as fever of unknown origin in an adult woman: a case report. | 2014 | J Med Case Rep | pmid:25084829 |
Bilgin M et al. | Acute coronary syndrome secondary to clarithromycin: the first case and review of the literature. | 2014 | Turk Kardiyol Dern Ars | pmid:25080953 |
Hsu PI et al. | Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection. | 2014 | Antimicrob. Agents Chemother. | pmid:25070099 |
Patel SK et al. | Helicobacter pylori is not eradicated after triple therapy: a nested PCR based study. | 2014 | Biomed Res Int | pmid:25054141 |
Klesiewicz K et al. | PCR-RFLP detection of point mutations A2143G and A2142G in 23S rRNA gene conferring resistance to clarithromycin in Helicobacter pylori strains. | 2014 | Acta Biochim. Pol. | pmid:24927236 |
Sugimoto M and Furuta T | Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype. | 2014 | World J. Gastroenterol. | pmid:24914361 |
Heo J and Jeon SW | Optimal treatment strategy for Helicobacter pylori: era of antibiotic resistance. | 2014 | World J. Gastroenterol. | pmid:24914324 |
Glatz M and Muellegger RR | Drug-associated aquagenic wrinkling of the palms in an atopic male patient. | 2014 | BMJ Case Rep | pmid:24903725 |
Sugimoto M et al. | Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion. | 2014 | Helicobacter | pmid:24690010 |
Liu KY et al. | Efficacy and pharmacological mechanism of pronase-enhanced low-dose antibiotics for Helicobacter pylori eradication. | 2014 | Antimicrob. Agents Chemother. | pmid:24687504 |
Ikawa K et al. | Pharmacokinetic modelling of serum and bronchial concentrations for clarithromycin and telithromycin, and site-specific pharmacodynamic simulation for their dosages. | 2014 | J Clin Pharm Ther | pmid:24661290 |
Varvyanskaya A and Lopatin A | Efficacy of long-term low-dose macrolide therapy in preventing early recurrence of nasal polyps after endoscopic sinus surgery. | 2014 | Int Forum Allergy Rhinol | pmid:24659566 |
Lee SH et al. | Detection and assessment of clarithromycin inducible resistant strains among Korean Mycobacterium abscessus clinical strains: PCR methods. | 2014 | J. Clin. Lab. Anal. | pmid:24652818 |
Binh TT et al. | Discovery of novel mutations for clarithromycin resistance in Helicobacter pylori by using next-generation sequencing. | 2014 | J. Antimicrob. Chemother. | pmid:24648504 |
Karaolia P et al. | Reduction of clarithromycin and sulfamethoxazole-resistant Enterococcus by pilot-scale solar-driven Fenton oxidation. | 2014 | Sci. Total Environ. | pmid:24012892 |
Rizzo A et al. | Antimicrobial effect of natural polyphenols with or without antibiotics on Chlamydia pneumoniae infection in vitro. | 2014 | Microb. Drug Resist. | pmid:23952319 |
Zhang J et al. | Ocular penetration and pharmacokinetics of topical clarithromycin eye drops to rabbits. | 2014 | J Ocul Pharmacol Ther | pmid:24199739 |
Ali Habib HS et al. | Effect of sequential versus standard Helicobacter pylori eradication therapy on the associated iron deficiency anemia in children. | 2013 Sep-Oct | Indian J Pharmacol | pmid:24130381 |
Mégraud F | Current recommendations for Helicobacter pylori therapies in a world of evolving resistance. | 2013 Nov-Dec | Gut Microbes | pmid:23929066 |
Suzaki I et al. | Enhancement of thioredoxin production from nasal epithelial cells by the macrolide antibiotic, clarithromycin in vitro. | 2013 May-Jun | In Vivo | pmid:23606690 |
Dajani AI et al. | Do probiotics improve eradication response to Helicobacter pylori on standard triple or sequential therapy? | 2013 May-Jun | Saudi J Gastroenterol | pmid:23680708 |
Petitto J et al. | Successful clarithromycin desensitization in a macrolide-sensitive pediatric patient. | 2013 May-Jun | J Allergy Clin Immunol Pract | pmid:24565493 |
Cottle LE et al. | A multinational outbreak of histoplasmosis following a biology field trip in the Ugandan rainforest. | 2013 Mar-Apr | J Travel Med | pmid:23464714 |
Molina-Infante J and Gisbert JP | [Update on the efficacy of triple therapy for Helicobacter pylori infection and clarithromycin resistance rates in Spain (2007-2012)]. | 2013 Jun-Jul | Gastroenterol Hepatol | pmid:23623461 |
Razafimahefa SH et al. | [Helicobacter pylori: what eradication regimen in a tropical area after the failure of two separate lines of eradication including metronidazole and clarithromycin?]. | 2013 Jan-Mar | Med Sante Trop | pmid:23360589 |
Mandras N et al. | Antibacterial efficacy and drug-induced tooth discolouration of antibiotic combinations for endodontic regenerative procedures. | 2013 Apr-Jun | Int J Immunopathol Pharmacol | pmid:23755774 |
Auw-Hädrich C et al. | [Clarithromycin for monotherapy of B-cell MALT lymphoma?]. | 2013 | Ophthalmologe | pmid:24231914 |
Haas K | [Reply]. | 2013 | Ophthalmologe | pmid:24377112 |
Kale-Pradhan PB et al. | The role of antimicrobials in Crohn's disease. | 2013 | Expert Rev Gastroenterol Hepatol | pmid:23445237 |
Kate V et al. | Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a systematic review of recent evidence. | 2013 | Drugs | pmid:23625272 |
Fiorini G et al. | Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection. | 2013 | Clin. Gastroenterol. Hepatol. | pmid:23267869 |
Gisbert JP et al. | Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection. | 2013 | Scand. J. Gastroenterol. | pmid:23556551 |
Pilcer G et al. | New co-spray-dried tobramycin nanoparticles-clarithromycin inhaled powder systems for lung infection therapy in cystic fibrosis patients. | 2013 | J Pharm Sci | pmid:23568616 |